SEARCH
Who We Are
Organisational Structure
Our Council and Expert Panels
Committees We Serve
Careers at ACE
Our Impact
Healthcare Professionals
ACE Clinical Guidances (ACGs)
ACE CUES
ACE Technology Guidances
ACE Horizon Scanning
Patients & Community
Asthma Resources
CEE Updates
Educational Resources
Learning Modules for Patients and the Public
Opportunities for Patient Involvement
Plain English Summaries
Resources
Methods & Process
Scientific Publications
Video Resources
Archives
News
Announcements
Events
Newsletter
search
SEARCH
Home
Healthcare Professionals
Healthcare Professionals
ACE Clinical Guidances (ACGs)
View Guidances
ACE CUES
Find Out More
ACE Technology Guidances
View Guidances
Published on 27 Jul 2021
Last Updated on 17 Aug 2021
A-
A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Dacomitinib 15 mg, 30 mg and 45 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.
Subsidy status
Dacomitinib 15 mg, 30 mg and 45 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) with effect from 3 August 2021.
Dacomitinib for treating EGFR mutation-positive NSCLC (17 Aug 2021)
Dacomitinib for treating EGFR mutation-positive NSCLC PES (27 Jul 2021)